The Bombay High Court asked the government to remove the "incorrect" public perception that only Tocilizumab can treat the inflammatory burst conditions in COVID-19 patients. It said that "all-out" efforts should be made by the government to remove the perception as the government itself said that "Itolizumab, Dexamethasone, and Methylprednisolone are equivalent and/or better than Tocilizumab".